d integrated FFR lesion severity assessment.
Mr. Huennekens continued, "By adding high resolution rotational IVUS and
pressure-based FFR to our phased array s5 imaging platform, we provide a
level of technology, clinical utility and convenience that is un-matched in
the intravascular imaging field. No other company provides a system that
integrates this level of functionality and convenience in a single
platform. Our message now is simple: Volcano offers physicians all three
technologies on one system -- you can choose which technology is best for
your patient and clinical team."
Earlier generation consoles included only one of the three technologies
now available on the s5i. If a hospital wanted to equip a new lab with all
three technologies, they would have to acquire three separate consoles,
each with a different measurement modality, training requirements and data
storage protocols. The Volcano s5i can now accommodate three primary
intravascular diagnostic tools in regular use by cardiologists today (high
frequency rotational IVUS, fast and simple phased array IVUS, and
pressure-based FFR guidewires) on a single platform, making Volcano's s5
and s5i imaging systems more flexible than ever before.
Presence at EuroPCR08
Volcano's presence at the EuroPCR 2008 Congress in Barcelona will
include live case transmissions with IVUS, FFR, and OCT, scientific
symposia sponsorship, first-in-man clinical experience and live product
demonstrations at Volcano booth #B02. Volcano will also participate in the
following scientific symposia during the program.
Title Date & Time Location
"Controversies in Coronary
Intravascular Imaging" May 14th, 12:00 - 13:30 Room 3
"Optimizing stent implantation and
minimizing irradiation for complex
PCI" with GE Healthcare May 15th, 16:30 - 18:30 Room 6
"IVUS Virtual Histology for Physic
'/>"/>
SOURCE Volcano Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter2.
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent3.
Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR4.
Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast5.
Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console6.
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast7.
Volcano Announces Closing of CardioSpectra Acquisition8.
Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated9.
Volcano Corporation Announces Pricing of Common Stock Offering10.
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast11.
NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect